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Background: The human ether-a-go-go related gene 1 (hERG1), which codes for a potassium ion channel, is a key
element in the cardiac delayed rectified potassium current, IKr, and plays an important role in the normal repolarization
of the heart’s action potential. Many approved drugs have been withdrawn from the market due to their prolongation
of the QT interval. Most of these drugs have high potencies for their principal targets and are often irreplaceable, thus
“rehabilitation” studies for decreasing their high hERG1 blocking affinities, while keeping them active at the binding sites
of their targets, have been proposed to enable these drugs to re-enter the market.
Methods: In this proof-of-principle study, we focus on cisapride, a gastroprokinetic agent withdrawn from the market
due to its high hERG1 blocking affinity. Here we tested an a priori strategy to predict a compound’s cardiotoxicity using
de novo drug design with molecular docking and Molecular Dynamics (MD) simulations to generate a strategy for the
rehabilitation of cisapride.
Results: We focused on two key receptors, a target interaction with the (adenosine) receptor and an off-target interaction
with hERG1 channels. An analysis of the fragment interactions of cisapride at human A2A adenosine receptors and hERG1
central cavities helped us to identify the key chemical groups responsible for the drug activity and hERG1 blockade. A set
of cisapride derivatives with reduced cardiotoxicity was then proposed using an in-silico two-tier approach. This set was
compared against a large dataset of commercially available cisapride analogs and derivatives.
Conclusions: An interaction decomposition of cisapride and cisapride derivatives allowed for the identification of key
active scaffolds and functional groups that may be responsible for the unwanted blockade of hERG1.
Keywords: hERG K channel, A2A adenosine receptor, 5HT-4 receptor, Molecular docking, Molecular dynamics simulations,
Drug design, Drug databasesBackground
Several classes of potassium channels are involved in regu-
lating the heart rate by setting the amplitude and duration
of the action potential and the resting membrane poten-
tial. Abnormalities in the function of these ion channels
due to inherited mutations or pharmacological blockage
can prolong the duration of the action potential, leading
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unless otherwise stated.syndromes - LQTS). Genetic analysis has revealed that
mutations in potassium channels, such as the human
ether-a-go-go related gene (hERG) and KvLQT1, establish
a molecular basis for LQTS [1-4]. A growing number of
diseases have also been linked to genetic mutations in
potassium channels. The channelopathies related to po-
tassium channels include various cancer types, type 2
Bartter’s syndrome, type 1 episodic ataxia, and hyper-
insulinemic hypoglycemia [4]. The best-known feature
of the hERG1 channel is its unique promiscuity in bind-
ing to a wide range of organic molecules. A broad panel
of organic compounds used in common cardiac and
non-cardiac medications (e.g., antibiotics, antihista-
mines and antibacterial agents) are thought to cause al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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central cavity of hERG and similar channels, leading
to ventricular arrhythmia [5]. Several Food and Drug
Administration (FDA) approved drugs (i.e., terfena-
dine, cisapride, astemizole and grepafloxin) have been
withdrawn from the market, while others like thiorida-
zine, haloperidol, sertindole, and pimozide have been
restricted due to their effect on the function of the
hERG channel. The discovery of drug-related arrhyth-
mias has led to mandatory drug screening for hERG1
blockage by both the FDA and the European Medicines
Agency (EMEA). Because most of these drugs have
high binding affinity profiles for their principal targets,
“rehabilitation” studies aimed at reducing their side
effects (i.e., decreasing their high hERG1 blocking af-
finities) while keeping them efficient at binding to their
original targets have become increasingly common.
These studies may allow these drugs to reenter the
market.
We chose cisapride to study as a model hERG blocker
that can potentially be rehabilitated and returned back to
the market. Researchers at Janssen Pharmaceutica discov-
ered cisapride (a gastroprokinetic agent; trade names: pre-
pulsid, propulsid) in 1980. Cisapride, a prokinetic agent,
increases gastrointestinal motility and acts as a selective
serotonin agonist for 5HT-4 receptors. It also relieves
gastrointestinal symptoms (i.e., constipation and bloating)
by indirectly stimulating the release of acetylcholine in
muscarinic receptors. In the gastrointestinal tract, the acti-
vation of these receptors stimulates smooth muscle con-
traction. While cisapride’s main target is thought to be the
5-hydroxytryptamine receptor 4 (5HT-4), it can selectivelyFigure 1 The block-scheme for the work-flow in the computational retarget a number of other G-protein-coupled receptors
(GPCRs). For example, cisapride has binding affinities for
5HT-4 (~14 nM) and adrenergic receptors (16 nM at the
α-1 adrenergic receptor). Cisapride was marketed in the
USA from 1993 to 2000; the use of cisapride has been
associated with 341 reports of cardiovascular problems,
including LQTS and torsades-de-pointes, and 80 re-
ports of death [6]. After seven years on the market, cisa-
pride was withdrawn in the USA and was limited for
use in many other countries due to its high hERG1
blocking affinity (IC50 6.5 nM, Mohammad et al. [7];
IC50 44.5 nM, Rampe et al. [8,9]; IC50 15.0 nM Drolet
et al. [10]). A goal of our proof-of-principle study is to
establish the feasibility of an in silico cardiotoxicity as-
sessment with a multi-target computational approach
for rehabilitation that:
(i) Assesses drugs for their hERG-blocking ability;
(ii) Identify the active components responsible for the
original target activity;
(iii) Caps or modifies the moieties responsible for the
hERG blockade.
The workflow chart is shown in Figure 1. We combined
step-by-step ligand modification focusing on key func-
tional groups (Figure 2), two-target receptor docking,
and molecular dynamics (MD) simulations to achieve this
goal. First, we determined the key-molecular fragments of
cisapride responsible for its high-affinity binding to the
A2A receptor using all-atom MD simulations and Mole-
cular Mechanics/Generalized Born Surface Area (MM/
GBSA) binding energy decompositions, which are similarhabilitation of cisapride derivatives.
Figure 2 The group definition of cisapride (i.e., R1 = -C6H4-F;
R2 = -O-CH2-; R3 = -CH2-CH2-; R4 = -C5H3N-O-CH3; R5 = -NH-CO-;
R6 = C6H2-Cl-NH2; R7 = -O-CH3) for per-group decomposition
and inter-monomer contacts from the MM/GBSA analysis.
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small modifications of the sites responsible for the
hERG blockade that played a less significant role in the
stabilization of cisapride in the binding pocket of the A2A
receptor were made. Our previously developed atomistic
models of the open-state hERG1 channel were used to
guide the modifications of cisapride. The most potent
drug variants were tested for their binding to the cen-
tral cavity of the hERG1 channel. The compounds that
showed low affinities were then selected for further
analysis. Because no crystal structure of the 5HT-4 re-
ceptor is currently available, we used a recently crystal-
lized agonist-bound active GPCR from the same family
as the target (the human adenosine A2A receptor, PDB
ID: 3QAK) [14]. Since cisapride can selectively bind to
a number of other GPCRs (including A2A receptor)
with a similar range of binding affinity at a similar
binding pocket, we chose to work with the available
agonist-bound active target site of the A2A receptor to
screen cisapride and its derivatives. Prior binding site
[15] and comparative homology modeling studies for
these receptors indicate a high similarity between the
5HT-4 and A2A binding pockets. Finally, a list of pos-
sible modifications to the original cisapride molecule
was generated. MD simulations with MM/GB-SA com-
putations, database drug screening and de novo design
studies clearly showed that the shorter alkyl chain in
cisapride analogues are key to retaining their binding
to the A2A receptor while remediating the blockade
of the hERG1 channel. To compare in silico results to
de novo developments we screened a large panel of
already synthesized cisapride analogs. Small molecule
databanks (i.e., ZINC [16]) were screened for synthesized
cisapride derivatives and the relevant literature was re-
viewed to identify their activity in both the GPCR and
hERG targets. Dual target docking combined with all-
atom MD simulations were used to establish the keyinteractions between cisapride and its derivatives re-
sponsible for their high-affinity binding to the A2A and
how they receptor triggering hERG1 blockade. Using
this combination of techniques it is possible to assess
novel compounds a priori for their cardiotoxicity risks
associated with hERG1 blockade as well as to identify




The structures were initially optimized using Schrodinger’s
Macromodel module to perform an all-atom MM geom-
etry optimization. The optimization was carried out with
the OPLS 2005 force field and the Polak-Rebiere Conju-
gate Gradient (PRCG) energy minimization method with a
0.001 kcal mol−1 Å−1 energy gradient convergence criter-
ion [17]. The resultant ligand structures were docked to
the targets using the following docking algorithms: Glide/
Induced Fit Docking (IFD) [18], FlexX [19], Autodock
[20], and Generalized Optimized Ligand Docking (GOLD)
[21]. The details of the docking algorithms are described
below:
Glide/IFD: The Glide-XP (extra precision) (v.5.0) and
Induced Fit Docking (IFD) modules of the Maestro suite
were used for the docking calculations. The docking
studies were performed with the following steps: (i)
constrained minimization of the receptor with an root
mean square deviation (RMSD) with a cutoff of 0.18 Å;
(ii) initial Glide docking of each ligand using soft po-
tentials; (iii) refinement of the derived docking poses
(i.e., minimization of the docking poses within 20 Å of
the ligand poses) with Schrodinger’s Prime module; and
(iv) Glide re-docking of the protein-ligand complexes.
GOLD: The GOLD program (v.5.0.1) was used with two
default docking scores (GOLD Fitness and ChemScore).
Part of the receptor's flexibility was accounted for by
assigning flexibility to 10 specific amino acid residues at
the active site. The side chains of these amino acid resi-
dues were selected as flexible rotamers. The rotamers
progressed by 10° increments to cover a full 360° rota-
tion. The default genetic algorithm parameters (100 for
the population size, 5 for the number of islands, 100000
for the number of genetic operations and 2 for the niche
size) were used. However, the maximum number of
runs was set to 100 for each docking simulation. FlexX:
The FlexX program (v.4.0) from BioSolveIT was also
used. The default algorithm parameters were used for
the docking and construction of the active sites of the
receptor. The solutions per fragment and per iteration
were both set to 2000. AutoDock (v.4.0): The number of
grid points in each direction was 126 with a grid spacing
of 0.4 Å. The number of hybrid Genetic Algorithm-
Local Search (GA-LS) runs was 200.
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The SWISS-MODEL homology modeling program [22]
was used for the development of the 5HT-4 receptor
model. A multiple sequence alignment was performed
using the CLUSTALW algorithm [23]. A β1 adrenergic
receptor (A2A with a carvedilol agonist, PDB ID: 4AMJ)
was used as the template because it had the highest se-
quence identity percentage in the sequence alignment
(41%). Protein models were generated from the alignment
in a stepwise manner. The backbone coordinates for
the aligned positions were extracted from the template
and the regions of insertions/deletions in the alignment
were found by searching either a loop library or a con-
formational space search using constraint space program-
ming. The templates were weighted by their sequence
similarity to the target sequence and outlier atomic posi-
tions were excluded. The scoring function used for asses-
sing favorable interactions (hydrogen bonds, disulfide
bridges) and unfavorable close contacts for determining
side chain conformations was derived from a backbone-
dependent rotamer library [24].Figure 3 (left) Dynamics of cisapride in the hERG1 cavity (Backbone R
pore domain has an RMSD of ~2.9 Å). (right) Summary of the MM/GB-SA
from the last 40 ns of the MD simulation of the hERG1-cisapride complex.MD simulations
All-atom MD simulations were carried out using CHARMM
(v. c36a2) [25]. All simulations were carried out at
323 K and 1 atm using periodic boundary conditions
(PBC) with the NPT ensemble. The particle mesh
Ewald (PME) algorithm was used for the long-range
electrostatic interactions. Both the A2A receptor from
PDB coordinates [14] and a model of the hERG1 channel
[1,2,26] were embedded into the DPPC membrane bilayer
using the CHARMM-GUI membrane builder protocol
[27]. Structures were minimized and equilibrated with
gradually decreasing harmonic constraints (i.e., they
were initialized with 10.0 and 5.0 kcal mol−1 Å−2 for the
backbone and side chains, respectively, and gradually
decreased to 0.5 and 0.1 kcal mol−1 Å−2, respectively)
over 2 ns (for equilibration) and then subjected to a
50 ns production run.
MM/GBSA computations
The enthalpies of cisapride binding to both targets were
computed as averages from an ensemble of structuresMSD after 50 ns ~5.0 Å for a tetramer, 4.2 Å for a monomer; the
decomposition analysis (per-residue and per-group contributions)
(see Figure 2 for a definition of the R groups at cisapride).
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uted points over five independent 50 ns runs. The electro-
static contributions to the desolvation components of the
binding enthalpies were obtained by using the Generalized
Born Solvation Energy Module and an Implicit Membrane
(GBIM) module as implemented in CHARMM [28,29]. A
dielectric constant of 2 was assigned to the protein, and
the protein-solvent surface was defined using a set of opti-
mized atomic radii from Nina et al. [30]. Following the
numerical recipe of Chandra et al. [31], the membrane
was represented as a 24 Å slab with a dielectric constant
of 2. To better describe the lipid dynamics, we extracted
the positions of the lipid’s heavy atoms in the bilayer and
used them to represent the neutral slab around the protein
and cisapride. The protein-ligand interaction components
of the binding enthalpies were computed following a
standard protocol with infinite cut-offs [12,32].
Results and discussions
MD simulations
As stated in the Introduction, one of the major goals of
this study was to identify the determinants of theFigure 4 (left) The dynamics of cisapride in the A2A binding pocket (B
decomposition analysis (per-residue and per-group contributions) from the lacisapride blockade of hERG and its binding to the A2A
receptor which serves as a suitable model for the 5HT-4
receptor. Although our docking studies unambiguously
identified binding pockets in both proteins, the orienta-
tion of the bound ligand was less well defined. To ac-
count for the limited resolution of our docking studies,
we ran five independent 50 ns full-membrane all-atom
molecular dynamics (MD) simulations using the top 5
poses from docking analysis as a starting point. All sim-
ulations were found to produce stable trajectories with
membrane proteins displaying heavy atom RMSD values
of ~3 to 4 Å, which is comparable to root mean squared
fluctuation (RMSF) estimates from previous studies of
K-channels with available crystal structures [33]. The av-
eraged locations of the ligand after MD simulations are
shown in Figures 3 and 4. Cisapride bound in either
membrane protein (A2A receptor or hERG1 open-state
channel model) displays significant conformational dy-
namics in the binding site with an average RMSD value
of ~1.1 Å relative to the average structure. The back-
bone RMSD of the hERG tetramer channel after 50 ns
was approximately 5.3 Å including deviations from theackbone RMSD after 50 ns ~3.1 Å). (right) Summary of the MM/GB-SA
st 40 ns of the MD simulation of the A2A-cisapride complex.
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monomers were from 3.5 to 4.2 Å. The positional fluctu-
ations in backbone atoms of residues forming the pore
domain (PD) of the hERG1 monomer plateaued at a
RMSD of ~2.4-2.9 Å. These values are similar to those
reported previously for MD simulations of Kv channels
[32]. The backbone RMSDs of the A2A receptor plat-
eaued at ~3.1 Å. The considerable dynamics of the re-
ceptor and the bound ligand suggest that explicitly
accounting for site and ligand flexibility in evaluation of
the binding energies is necessary. To circumvent obvious
limitations of the chosen docking strategy and to identify
key interacting partners e.g. relevant amino-acid residues
and key functional groups in the drug, we performed
MM/GBSA computations to estimate the binding affinity
of cisapride in the A2A receptor and the open-state hERG1
model. The distribution of binding enthalpies from 5
independent simulations is shown in the Figure 5. The
average binding enthalpies for cisapride to the hERG1
and A2A are –21.3 ± 2.8 kcal/mol and -24.3 ± 1.9 kcal/
mol, respectively.
Analysis of the per-residue and per-functional group
contribution to binding enthalpies allows us to deter-
mine residues and drug fragments, which uniquely de-
termines the binding mode of cisapride in both systems.Figure 5 Normalized probability distribution function of the
binding enthalpies for cisapride to WT-A2A and WT-hERG1 proteins.(Figures 3 and 4) The key residues that determine the
thermodynamics of cisapride stabilization in the hERG1
cavity are S624 from the pore helix, Y652 and F656 from
the distal S6 and, surprisingly, W568 from the S5 helix.
The high-affinity intra-cavity blockade of hERG1 by cisa-
pride depends on the hydrogen bonds formed by the
pore-helix and on stabilizing aromatic interactions with
residues in the S5 and S6 helices. The drug dimensions
allow for inter-subunit interactions (see Figure 2) with
matching hydrophobic moieties in the hERG1 cavity while
the carbonyl backbone of cisapride interacts strongly
with T623 and S624. The binding mode is similar to that
for dofetilide and other molecules known to restrict
hERG1 K+ currents by binding to the protein’s internal
cavity [3,26]. Most of the residues were mapped in previ-
ous experimental studies and are thought to be respon-
sible for high-affinity blockades [34-38]. Importantly for
both systems, docking studies were able to identify key
amino acids and functional groups and thus results ob-
tained from average protein structure and flexible ligand
docking appear to be sufficiently predictive to allow for
micromanagement of the drug.
The decomposition of binding enthalpies for cisa-
pride binding to the A2A adenosine receptor is illus-
trated in Figure 4. While there is a cluster of acidic
residues involved in drug binding (E13, E169 and
D170), the desolvation penalty for the negative charges
located on the surface of the receptor counter balances
favorable charge interactions and contributes unfavor-
ably overall to drug stabilization in the pocket. Instead,
the bound cisapride is stabilized to a large extent by a
network of aromatic and amphipathic groups lining the
binding pocket. The constellation of residues includes
Y271, L267, I252, T256 and M270 that interact with the
linker and the rings (R1, R3, and R6). (See Figure X for
labeling of the regions of cisapride) The binding of cisa-
pride is further stabilized by interactions between the
residues S67, T68 and F168, and the moieties of the R2
and R3 regions. It is worth mentioning that all of these
residues are involved in the formation of binding
pockets for adenosine and other agonists, according to
previous studies and recently published crystal struc-
tures [14]. F168 forms binding interactions with the
central methoxy groups of the bound molecule, and
other key residues (S67, T68 and Y271) interact with
amphipathic functional groups on aromatic rings. The
molecular fragments of the drug that form stable inter-
actions with the residues in the A2A receptor are as fol-
lows: a methoxy group on the central heterocyclic ring
(R4), a terminal aromatic ring (R1), and a methoxy
group (R7) on the benzamide ring. Interestingly, it has
been shown that modification of the benzamide ring is
essential for modulation of the activity of cisapride de-
rivatives [39].
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cisapride on the A2A adenosine receptor binding and
blocking affinities of hERG1, we also performed per-group
decomposition of the binding enthalpies for drug binding
to hERG1. The cisapride fragments were defined accord-
ing to the topology definition of the CHARMM general
force field [25,40] and are illustrated in Figure 2. The
resulting decomposition is shown in Figures 3 and 4,
allowing us to focus on targeted modifications of the frag-
ments. It is apparent that to inhibit binding to hERG1, one
may need to modify one or both of the terminal rings (R1,
R6) as well as the flexible linkers (R2, R3). Cisapride
bound to the hERG1 cavity interacts with a ring of hydro-
phobic and aromatic residues (Y652, A653 and F656) and
the Ser/Thr-rich apex of the pore helix (T623, S624) [2].
Experimental studies have also demonstrated that the
matching interactions between cisapride and aromatic
rings (F656 and Y652) are essential for the hERG blockade
[41]. The decomposition analysis shows that one of the
key interactions important for the hERG blockade but un-
related to the high-affinity binding of cisapride to the A2A
receptor is the van-der-Waals interactions between the
long alkyl chain linker of the drug and a number of hydro-





The 10700 small organic molecules fragment database of Schrodinger was used to
found by a trajectory analysis of the MD simulations). Molecules were initially docke
docking for the promising derivatives (~500 compounds). Finally, the inhibitory prosimulations strategy adopted in this study appears to
have yielded a potential route to rehabilitate cisapride.
In our next step, we attempt to remove fragments re-
sponsible for drug stabilization in the inner-cavity of
hERG1 channel, while retaining its binding to the A2A
receptor. Several parallel approaches were considered
for de novo development of non-blocking cisapride col-
lected in Table 1:
(i) In the first approach, we simply targeted
heteroatoms in the functional groups of cisapride
molecule. They were exchanged with hydrogen (-H)
to observe the effect of each of these fragments on
the docking scores for both receptors.
(ii) Next, the number of –CH2 groups of the linker was
modified to produce truncated and extended
versions of the linker. This affects the distance
between the terminal aromatic ring and the
six-membered heterocyclic ring piperidine, thus
affecting torsional energy. The length of the alkyl
chain also modulates the interactions between the
aromatic moieties of the drug and the Y652/F656
residues that are key components of the high-








create new derivatives of cisapride (the place for replacement was previously
d using virtual high‐throughput screening (VHTS) with subsequent Glide/XP
files of these derivatives at hERG1 were tested using Induced Fit Docking.
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removed based on the per-fragment decomposition,
as shown in Figures 1 and 3.
A library of 10,700 molecules from the small organic
molecules fragment database of Maestro was used to
create new analogues of cisapride guided by energy de-
composition analysis as well as the per-residue inter-
action energy analysis described above. The summary of
the modification strategy is shown in Additional file 1:
Tables S1 to S2. All of the developed molecules were ini-
tially docked using virtual high throughput screening
(VHTS) followed by Glide extra precision (XP) docking
for the derivatives showing low hERG blocking bindingFigure 6 Ligand Binding to hERG1 pore domain. (i) The top-docking po
are zoomed and detailed (right). (ii) A 2D-ligand interaction map for cisaprscores and high binding scores for the A2A adenosine re-
ceptor (~500 compounds).
General note on molecular docking and De novo drug
design
All of the derived cisapride analogues were docked to
the A2A (PDB ID: 3QAK) active site using the approach
described in the methods section. They were also docked
to the pore domain of hERG1 model, and the cisapride
derivative results were compared to the original cisa-
pride docking scores. (Figures 6 and 7, and Additional
file 1: Table S1) Four different molecular docking pro-
grams (AutoDock, Glide, FlexX, and GOLD) were used
to study the binding interactions of cisapride and these of cisapride in the hERG1 pore domain. (left) Binding interactions
ide binding to the hERG cavity.
Figure 7 Ligand Binding to A2A receptor. Top panel: The top-docking pose of cisapride in the human A2A adenosine receptor. (left) Binding
interactions are zoomed and detailed (right). Bottom panel: A 2D-ligand interaction map for cisapride binding to the A2A receptor.
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the hERG1 central cavity. Since the FlexX and AutoDock
docking programs both underestimated the interaction
energies of cisapride and its derivatives at both targets
(i.e., hERG and A2A), GOLD and Glide/XP are generally
preferred for the evaluation of binding affinities of
known compounds. Our previously developed model
of the trans-membrane domains, S1-S6, of open-state
hERG1 [1,26] was used to model the binding interac-
tions of cisapride and its derivatives in the pore domain
of the channel. Initially, cisapride was docked to A2A
receptor as well as hERG1 model, and these binding
scores were used as threshold values for all four
docking programs. Cisapride derivatives that displayedsimilar/higher binding scores (absolute values) in the
A2A receptor and lower binding scores in the hERG1
pore domain were considered for further analysis. For
example, one of them (#11) labeled as Cisapride-D11
in the text had docking scores similar to original cisapride
in the A2A binding pocket and considerably lower docking
scores in the hERG PD, thus, it was considered for further
rehabilitation.
Effect of functional group substitution on drug binding to
A2A receptor and hERG1 channel
All of the candidates with hydrogen substitutions by het-
eroatoms (i.e., Cisapride-D1 and Cisapride-D8 in the
Additional file 1: Table S1) had docking scores similar to
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all of these derivatives retained high docking scores for
binding to the hERG PD and therefore were discarded.
Some of the new derivatives, such as Cisapride-D2 (an
exchange of a –Cl group with –H), led to a decrease in
the docking score in the A2A receptor (i.e., the Glide/XP
docking score decreased from -8.48 to -5.07 kcal/mole
for Cisapride-D2), thus these derivatives were also dis-
carded. (Additional file 1: Table S1) While the removal
of some functional groups from cisapride did not sig-
nificantly reduce the docking scores of compounds at
A2A, their hERG PD bindings were still too high (i.e.,
Cisapride-D4, Cisapride-D5).
Varying the number of –CH2 groups in the linker, R3
between the terminal aromatic ring, R1, and the central
heterocyclic ring, R4, affected the docking scores of
compounds in the hERG PD. (See Figure 2 for labeling)
While decreasing the number of -CH2 groups from
three (original cisapride) to one reduced the docking
score of the derivative in the hERG1 central cavity, (i.e.,
for Cisapride-D11, GOLD docking score went from -9.42
to -7.40 kcal/mole; the Glide/XP docking score went
from -7.80 to -7.09 kcal/mole) increasing the number
of –CH2 groups from 3 to 4 did not significantly affect
the docking score of the derivative in the hERG1 PD
(i.e., for Cisapride-D9, the GOLD docking score went
from -9.42 to -9.03 kcal/mole; the Glide/XP docking
score went from -7.80 to -7.45 kcal/mole) (Additional
file 1: Table S1). Therefor for further rehabilitation
studies, only a decreased number of –CH2 groups in
the cisapride backbone (i.e., Cisapride-D11) was con-
sidered. Derivatives of Cisapride-D11 were generated
using the Combinatorial Library Enumeration and Screen-
ing module of the Maestro molecular modeling package
and the corresponding docking results were compared
with that of original Cisapride-D11 (Additional file 1:
Table S2). For this purpose, approximately 600 default
fragments in Schrodinger’s Enumerate module were used,
and 8600 new cisapride derivatives were generated. After
the derivative generation, the compounds were prepared
(protonation states were determined at a pH of 7) with
the LigPrep module of Maestro and energy minimization
was performed for the structures using the PRCG energy
minimization method. Structures were then docked onto
the A2A adenosine receptor via the Glide High Through-
put Virtual Screening method (Glide/HTVS). This was
used to reduce the large number of derivatives to a man-
ageable number for further analysis. The top 100 com-
pounds according to the Glide/HTVS docking scores
were used for Glide extra precision (XP) docking both in
the A2A active site and the hERG1 central cavity. The
docking results of the selected derivatives of Cisapride-
D11 are tabulated in the Additional file 1: Table S2. One
of the major outcomes of this in silico study is that simpletruncation of the flexible linker appears to be sufficient to
remediate unwanted off-target interactions of cisapride.
Obviously, it is not sufficient just to claim that such modi-
fications will lead to a potent drug; it requires verification.
One of the reasons for choosing cisapride is the availability
of a large number of previously evaluated cisapride deriva-
tives. Accordingly, to test similarities and differences in
predicted cardiotoxicity (hERG1 blockade) and efficacy of
the cisapride derivatives we used the ZINC database and
literature mining.
Comparison study with a database of available
drug databases
94 cisapride derivatives (with >80% structural similarity
with cisapride) taken from the ZINC databank were
used to obtain the docking scores/poses for binding to
the human adenosine A2A receptor and the hERG1
pore domain using the Glide/XP docking program. The
compounds that had docking scores (absolute values)
greater than -7.00 kcal/mole in the A2A receptor bind-
ing site (28 cisapride derivatives) were evaluated for
their docking scores in the hERG PD (Additional file 1:
Tables S3 and S4). Results showed that a few promising
compounds (i.e., ZINC05998832, ZINC58529167, ZINC
13834042, ZINC20621758, ZINC43023913) with docking
scores less than (absolute values) -6.00 kcal/mole in the
hERG1 PD, and greater than (absolute values) -7.00 kcal/
mole in the binding pocket of the A2A receptor. (Table 2)
Interestingly, ZINC20621758, also known commer-
cially as mosapride, was detected via blinded dual-target
screening to be a safer 5HT-4 agonist than cisapride.
Potet et al. [6] showed that mosapride does not block
the hERG channel, which is in agreement with lower
binding scores predicted in silico. It is also a well-known
agonist of the 5HT-4 receptor. The IC50 of mosapride
binding to the hERG channel is ~16.5 μM. Mosapride
carries a significant decrease of cardiovascular risks re-
lated to alterations in QT intervals according to preclin-
ical studies [42,39,43]. Carlsson et al. used a rabbit
model of the acquired long QT syndrome, and while
cisapride prolonged the QT interval, mosapride did not
[39,44,45]. One of the key differences between mosa-
pride and cisapride is a shorter linker between aromatic
rings that, as predicted in the dual-target de novo drug
modeling, will have an immediate effect on the drug-
hERG PD interactions. Figure 8 shows the top Induced
Fit docking pose of mosapride in the A2A receptor. Cisa-
pride and mosapride have different binding modes in the
A2A receptor due to a different number of CH2 groups
in the linker. Additional file 1: Figure S2 shows a super-
position of the top-docking poses of cisapride and
mosapride.
The other ZINC compounds in Table 2 also exhibit
high docking scores in the A2A receptor; however there
Table 2 Cisapride derivatives from the ZINC database that show low binding scores in the hERG1 PD and high binding
scores in the A2A adenosine receptor
Cisapride derivatives 2D structure Glide XP docking
score @A2A (kcal/mol)
Glide XP docking
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these compounds. However, ZINC05998832 (aka fluoro-
clebopride) is a close analog of clebopride. The reported
IC50 of clebopride in the hERG PD is 0.62 μM. Clebo-
pride is commercially available in Spain and Italy as a
gastroprokinetic drug. Although its cardiotoxicity has
not been reported in clinical studies, in vitro studies
have shown that clebopride prolongs the cardiac action
potential duration at 90% (but not 50%) repolarization at
10 μM [44]. Tack et al. [44] also found that no cardio-
vascular safety concerns were reported for the newer se-
lective 5HT-4 agonists prucalopride, velusetrag, and
naronapride or for the non-selective 5HT-4 agonists
with no hERG or 5HT-1 affinity, such as renzapride, cle-
bopride, and mosapride. Importantly, the experimental
data available for several ZINC compounds indicated nMaffinity against 5HT-4 and 5HT-2 receptors, correspond-
ing to high affinity binding for several of the compounds
studied (ZINC20621758, Ki ~113 nM; ZINC43023913, 79
nM; ZINC13834042, 2250 nM and ZINC05998832 ~ 283
nM, respectively), all with very low docking scores in the
hERG PD. Although a few cisapride analogues (such as
ZINC28087327, Ki 40.6 nM in 5HT-4; ZINC43024452, Ki
3.16 nM in 5HT-4) were correctly predicted by in silico
screening to have high experimental binding affinities in
the 5HT-4 receptor, they also had high docking scores in
the hERG PD (Additional file 1: Tables S2 and S3).
On the transferability of A2A predictions to 5HT-4 receptors
There is a well-known challenge in relating the top bind-
ing poses produced by docking to the most stable ligand
orientations in the binding pocket. Many organic
Figure 8 Mosapride bidning to hERG1 pore domain. Top panel: The top-docking pose of mosapride that shows a low hERG PD blocking
affinity in the human A2A adenosine receptor. (left) Binding interactions are zoomed and detailed (right). Bottom panel: 2D-ligand interaction
map for mosapride binding to the A2A receptor.
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The previous section on mapping the relevant binding
sites in the receptor suggests that some of these residues
are also responsible for selective substrate and agonist
binding to human 5HT-4 [15,46]. It is worth mentioning
that the main target of cisapride in gastrointestinal tis-
sues is not the A2A receptor but the 5HT-4 receptor. To
investigate the similarities of the binding pockets of two
GPCRs, namely, 5HT-4 and A2A receptors, we per-
formed homology modeling with subsequent drug dock-
ing. The homology modeling was performed using
SWISS-MODEL for 5HT-4 (using the highest sequence
identity scores of a multiple sequence alignment). β1 ad-
renergic receptors (with agonist bound) resulted in thehighest sequence identity percentage from a sequence
alignment (41%) and it was used as a template. Superpos-
ition of the 5HT-4 model protein and the A2A crystal struc-
ture reconfirmed that there is high structural similarity
between these two GPCRs (RMSD of 2.4 Å) (Additional
file 1: Figure S1). Furthermore, most of the residues identi-
fied by MD simulations as essential for drug stabilization
are well-known determinants of high-affinity binding in
the 5HT-4 system. We also used the ChEMBL database to
search for compounds targeting the 5HT-4 receptor
(CHEMBL1875). ChEMBL is a database for bioactive
drug-like small molecules that contains abstracted experi-
mental bioactivities from the scientific literature (i.e., bind-
ing constants and pharmacology and ADME/Tox data)
Durdagi et al. BMC Pharmacology and Toxicology 2014, 15:14 Page 13 of 15
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5HT-4 receptor were found. The results were ranked based
on Ki values, and compounds that had better Ki values
than 1 nM in the 5HT-4 receptor were kept for consider-
ation. Our aim was to test the docking score accuracies for
compounds in the binding pockets of the A2A and 5HT-4
receptors. The protonation states were determined at
pH 7, and structures were optimized using the LigPrep
module of Maestro. Subsequently, these compounds were
docked to the A2A and 5HT-4 receptors using Glide/XP
Induced Fit Docking. Considering the simplicity of the
docking approach, our results show a high correlation
between the experimental and predicted binding ener-
gies (r2 > 0.6 for both compounds in the A2A and 5HT-Figure 9 Comparison of experimental and calculated (IFD docking sco
and Bottom panel: The 5HT-4 receptor. (Ki values are converted to kcal/mo
different Ki values for same target, the average of these values is used).4 receptors, docking results, Figure 9). Structures with
bioactivity results in the 5HT-4 receptor were also
docked in the hERG PD using Induced Fit Docking.
Compounds with low predicted binding affinities in the
hERG PD are listed in Additional file 1: Table S5 and
can guide future studies. Our findings reconfirm the
similarity of the binding pockets of the A2A and 5HT-4
receptors as well as the transferability of our results.
Conclusions
A cross analysis of the interactions between cisapride
and its analogues with the human A2A adenosine recep-
tor and the hERG1 central cavity led us to formulate a
computational approach to the rehabilitation of drugsres) binding energies of compounds. Top panel: The A2A receptor
le for comparison, T = 300 K, R = 8.314 J/molK; If a compound has
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ity. Our SAR study of cisapride and its derivatives allows
for the in silico evaluation of drug potency and the
drug’s ability to block hERG. Molecular docking results
using both de novo designed compounds and available
cisapride derivatives in the ZINC drug database showed
that the shorter alkyl chains in the cisapride analogues is
key element to retaining their binding to the A2A recep-
tor and remediating the blockade of the hERG1 channel.
We believe that a simple dual-target ‘rehabilitation’
strategy based on an optimization against two protein
target structures may be applied to other drugs with-
drawn from the market due to their side effects, and
may lead to the reuse of these drugs.
Additional file
Additional file 1: Summary of Docking, De Novo Design and
Modeling studies for cisapride analogues investigated.
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